Off-label marketing: the competition for “biggest corporate fine” gets juicy

It is so important to admit when you’re wrong.  So here goes… When I wrote that Astra-Zeneca paid the biggest corporate fine in American history ($520 million) for the off-label marketing of Seroquel, an atypical antipsychotic [I wrote that here]; I was wrong. (NOTE: off-label marketing is the promotion of a drug – whether amongst patients, doctors, or other […]

Warning now out of a bunch of “mood-stabilizers”

UPDATED: IT WAS A WARNING NOT A BLACK BOX WARNING I’ve been seeing this everywhere for the last 24 hours or so, but haven’t felt like dealing with getting it up here. It’s something lot’s of you will want to know though. Many of these drugs are only used for seizure disorders…but a good number […]

Atypical antipsychotics: too hard a sell? Let’s hope so!!

As some of you may know the FDA is reviewing the use of Seroquel for all sorts of stuff at the bequest of AstraZeneca. I’ve covered it a bit here but many others have done a better job. Look here at Furious Seasons for good background info. Here is the latest tid-bit from the LA […]

Lexapro squeaks by FDA approval for teens

Read Philip’s inside scoop…he concludes his research with this paragraph. So we have two failed studies and a positive study of Celexa with a very small effect size plus a poster presentation of Lexapro and that’s what the FDA based its approval of Lexapro for teens upon. My guess is that this drug just barely […]

Prescription for Disaster—Gary Null

This video is about 3 years old. Unfortunately nothing has changed and things perhaps have gotten worse. Do you know that atypical neuroleptics have killed many many more people than Vioxx ever did? He starts this video talking about Vioxx. We need to ask why the most vulnerable people in society are so disrespected that […]